Condition: Aortic Regurgitation · Aortic Valve Insufficiency · Aortic Insufficiency · Sponsor: JenaValve Technology, Inc.
To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)
This description comes directly from the study's public registry record.
Duane Pinto, MD MPH · 949-767-2110 · pinto@jenavalve.com
Always discuss trial participation with your own doctor first.
| CPMC Sutter Health | Burlingame, California, United States | Recruiting |
| Scripps Health | La Jolla, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Los Robles Medical Center | Thousand Oaks, California, United States | Recruiting |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | Recruiting |
| BayCare Health | Clearwater, Florida, United States | Recruiting |
| HCA North Florida | Gainesville, Florida, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Piedmont Healthcare | Atlanta, Georgia, United States | Recruiting |
| Heart Care Centers of IL / Hinsdale Hospital | Chicago, Illinois, United States | Recruiting |
| Ascension St. Vincent Heart Center | Carmel, Indiana, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06608823